U.S. market Closed. Opens in 1 hour 14 minutes

INVA | Innoviva, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 18.97 - 19.22
52 Week Range 13.46 - 21.28
Beta 0.55
Implied Volatility 39.02%
IV Rank 24.64%
Day's Volume 1,238,451
Average Volume 540,554
Shares Outstanding 62,601,100
Market Cap 1,198,811,065
Sector Healthcare
Industry Biotechnology
IPO Date 2004-10-05
Valuation
Profitability
Growth
Health
P/E Ratio 23.64
Forward P/E Ratio N/A
EPS 0.81
1YR Price Target 17.75
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 112
Country USA
Website INVA
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
INVA's peers: GTX, EFTR, PLX, PDSB, LIFE, ELEV, DAWN, MRTX, AMLX, TERN, APLS, XFOR, INZY, HOOK, ABOS, FOLD, INCY, DNLI, ARGX, HRMY
*Chart delayed
Analyzing fundamentals for INVA we got that it has strong fundamentals where Valuation is considered to be undervalued, Profitability is stunning wealthy, Growth is good and Health is very strong. For more detailed analysis please see INVA Fundamentals page.

Watching at INVA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on INVA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙